Interested in learning more about Wistar Science or meeting any of our Wistar experts? You can find the latest details below, or feel free to contact Darien Sutton using the contact information at left.
PRESS RELEASE CONTACT: Darien Sutton 215-898-3988 | dsutton@wistar.org PHILADELPHIA — (July 10, 2025) — Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs…
PRESS RELEASE CONTACT: Darien Sutton 215-898-3988 | dsutton@wistar.org PHILADELPHIA — (JULY 9, 2025) — Scientists at The Wistar Institute have discovered how a key protein from the Epstein-Barr vir…
The Wistar Institute, a world leader in cancer, immunology, and infectious disease research, announces the appointment of Qingsheng Li, Ph.D., as professor in the HIV Cure and Viral Diseases Center…
PHILADELPHIA — (May 28, 2025) — The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Joshua Friedman, M.D., Ph.D., to its B…
PHILADELPHIA — (May 22, 2025) — Researchers at The Wistar Institute have identified a previously unknown mechanism by which viruses can reprogram mitochondrial structure to silence immune responses a…
PHILADELPHIA — (April 30, 2025) —The Wistar Institute, a world leader in cancer, immunology, and infectious disease research, announces the appointment of Xiaoyu (Ariel) Zhou, Ph.D., as assistant pro…
PHILADELPHIA — (April 9, 2025) —The Wistar Institute’s Joseph Salvino, Ph.D., — in collaboration with Elton Zeqiraj, Ph.D., of The University of Leeds and Roger Greenberg, M.D., Ph.D., of The Perelma…
PHILADELPHIA — (March 21, 2025) — Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., in collaboration with scientists in the laboratory of Norbert Pardi, Ph.D., at the University of Pe…
PHILADELPHIA — (March 20, 2025) — The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome three new members to its Board of Tr…
PHILADELPHIA — (March 10, 2025) — The Wistar Institute’s Paul M. Lieberman, Ph.D. and lab identified and tested a new method for targeting certain cancers caused by Epstein-Barr Virus (EBV), in the p…
